ABVC BioPharma Inc. (ABVC)
ABVC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/0001213900-26-023063-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABVC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001173313 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $296K |
| Net income | -$7.9M |
| Operating income | -$7.2M |
| Net margin | -2671.8% |
| Operating margin | -2416.0% |
| Revenue growth | -41.9% |
| Cash | $681K |
| Total assets | $21.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 85.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $11K cash; operating cash flow -$541K a quarter. | Report 2026-09-30 |
| Shares outstanding | 26,976,625 (2026-11-09); 24,301,089 a year earlier; 7,231,940 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Simon & Edward, LLP, Rowland Heights, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-07-02 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | $1.1M | -$439K | $11K | $30K | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$737K | -$244K | $32K | $59K | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$1.6M | -$894K | $140K | $89K | Needs four quarters | 10-Q 2026-05-18 |
| Q4 2025 2025-12-31 | -$500K | -$2.8M | -$588K | $681K | $756K | $296K | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $796K | -$2.0M | -$965K | $192K | $1.3M | Needs four quarters | 10-Q 2025-11-03 |
| Q2 2025 2025-06-30 | Not filed | -$2.3M | -$894K | $388K | $1.1M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$842K | -$540K | $152K | $810K | Needs four quarters | 10-Q 2026-05-18 |
| Q4 2024 2024-12-31 | $2K | -$732K | -$702K | $248K | $1.8M | $510K | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B4 | 2026-11-13 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-03 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-10 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-02 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-09-29 |
Source: SEC EDGAR submissions feed, 803 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.1% |
| 1 month | -7.0% |
| 3 months | -5.1% |
| Year to date | -57.3% |
| 1 year | -67.5% |
| From 52-week high | -68.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier